AusCann Group completes capital raising

Company News

by Rachael Jones

Leading medical cannabis company AusCann Group (ASX:AC8) has successfully completed a capital raising of $33.4 million via a share placement to sophisticated and professional investors from North America and Australia, including AusCann’s major shareholder, Canopy Growth Corporation.

Canopy will increase its ownership in AusCann to 11.2 per cent following completion of the Placement.

AusCann will use the proceeds of the Placement to fund cannabinoid pharmaceutical research and development and clinical studies and expand its operations in Chile and Australia.

Canaccord Genuity Australia acted as lead manager and bookrunner to the Placement.

The Company intends to offer an SPP to eligible existing shareholders

Shares in AusCann Group (ASX:AC8)down 6.25% to $1.20
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.